DoNotAge Pure Apigenin Supplement - Evidence-Based Review
Apigenin is a plant flavone (4',5,7-trihydroxyflavone) studied as a small-molecule inhibitor of CD38 — the NAD-consuming enzyme whose age-related upregulation is one of the proposed drivers of declining NAD+ pools. DoNotAge's Pure Apigenin delivers 250 mg per capsule, with a recommended daily intake of 500 mg. The principal evidence for the CD38-mediated NAD+ effect is mouse data; human data at this oral dose is not yet available. Customer reviews predominantly describe this product as a sleep / calm-down supplement — the editorial copy below addresses both the NAD+ positioning and the sleep use case honestly.
- CD38 → NAD+ doubling is mouse data (Escande 2013); human NAD+ effect at 500 mg/day oral dose has not been independently replicated.
- Sourced from grapefruit naringin via a synthetic conversion step; "naturally derived" is technically accurate but worth understanding.
- Oral bioavailability is poor (~30%); plasma concentrations from realistic doses fall well below the in-vitro CD38-inhibitory range.
- Single-ingredient, fully-disclosed formula: 250 mg apigenin per vegetable cellulose capsule, no fillers, third-party tested above 99% purity.
- 14-day money-back guarantee on unopened tubs; 50% refund on opened tubs with ≥50% remaining.
- Delivery: USA 2–3 days, UK 2 days, EU 3–4 days, Worldwide 3–7 days.
Pure Apigenin at a glance
Pure Apigenin is a single-ingredient flavonoid supplement at a defined per-capsule dose. Unlike a blended product, the per-ingredient transparency frontier here is not the dose breakdown (there is only one active) but rather: the form of apigenin delivered, the pharmacokinetic profile after oral administration, and how realistic plasma levels compare to the in-vitro concentrations at which CD38 inhibition has been demonstrated. The fact set below addresses each of those.
HOW IT WORKS
Six pathways apigenin acts on — and what's actually demonstrated
Apigenin is a small molecule with broad pharmacological activity across multiple cellular pathways. The six mechanisms below are the ones with the strongest mechanistic support in the published literature. For each, we describe the molecular target, the level of evidence (in vitro, animal, or human), and whether the in vivo plasma levels achievable from 500 mg/day oral dosing are likely to reach the concentrations at which the in-vitro effect has been demonstrated.
Apigenin is one of the most potent natural inhibitors of the NAD-consuming enzyme CD38. In mice, this raises tissue NAD+ levels.
CD38 is a multifunctional ectoenzyme that hydrolyses NAD+ as one of its activities. CD38 expression increases with age across multiple tissues (Camacho-Pereira 2016) and is one of the proposed mechanistic drivers of the well-documented age-related decline in NAD+. Apigenin was identified by Escande et al. (2013) as one of a small group of flavonoids that inhibit CD38; in cell culture, apigenin reduces CD38 enzymatic activity, and in mice fed apigenin-supplemented diets, tissue NAD+ levels approximately doubled with concurrent improvements in metabolic parameters. The dose used in the Escande mouse work was approximately 100 mg/kg/day mixed into chow, which body-surface-area-corrects to roughly 8 mg/kg for a human (around 560 mg/day for a 70 kg adult — broadly consistent with the 500 mg/day DoNotAge recommendation). However, two important caveats apply when translating the mouse result to humans: (1) the in-vitro IC50 of apigenin against CD38 is in the low-to-mid micromolar range, while plasma concentrations from realistic oral doses in humans are in the low nanomolar range (Meyer 2006: 33.46 nmol/L peak from 2 g/kg parsley), implying that systemic plasma levels at 500 mg/day are likely 100–1000× below the in-vitro inhibitory concentration; (2) no human RCT has directly measured NAD+ elevation after oral apigenin supplementation at 500 mg/day. The CD38 inhibition mechanism is real and the mouse evidence is solid; the magnitude of effect in humans at the recommended dose is not yet established.
Apigenin binds the benzodiazepine receptor as a partial agonist — the mechanism behind chamomile's calming effect.
Viola et al. (1995) identified apigenin as the principal active ligand in chamomile (Matricaria recutita) flowers responsible for the herb's anxiolytic effect. Apigenin binds the central benzodiazepine binding site on the GABA-A receptor with affinity in the low micromolar range, acting as a partial agonist — meaning it produces a calming, anxiolytic-like effect at higher doses without the full sedative, amnestic, or dependence profile of clinical benzodiazepines such as diazepam. Avallone et al. (2000) confirmed and extended this finding, showing that apigenin produces anxiolytic-like behavioural effects in rodents at doses that do not cause sedation or impair locomotor performance. This is the mechanistic basis for chamomile's reputation as a calming, sleep-supporting herb, and is the most likely mechanism behind the substantial customer-review pattern of using Pure Apigenin specifically for sleep onset and evening calm. The caveat: as with the CD38 pathway, the in-vitro binding affinity is in the low micromolar range while plasma free apigenin from 500 mg oral is likely in the low nanomolar range. A meaningful CNS effect would depend on either (a) local conjugate hydrolysis releasing free apigenin in tissue, (b) the brain penetration of apigenin metabolites with partial activity at the receptor, or (c) effects mediated by lower-dose, longer-duration exposure than the in-vitro IC50 implies.
Apigenin suppresses the major inflammatory transcription pathway (NF-κB) and downstream inducible enzymes (COX-2, iNOS) in macrophages and other cell types.
Liang et al. (1999, PMID 10506109) demonstrated that apigenin and structurally related flavonoids suppress lipopolysaccharide-induced expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in mouse macrophages — both downstream of NF-κB activation. The pathway has since been replicated extensively in vitro across multiple cell types. The clinical implications: the molecular basis is genuine and well-replicated, but the in-vitro concentrations used (typically 10–50 μM) are again above what oral 500 mg/day is likely to deliver systemically. Local effects in the gastrointestinal tract — where apigenin reaches relatively high luminal concentrations before absorption and conjugation — are more plausible than systemic anti-inflammatory effects, and apigenin has shown gastroprotective effects in animal models that may relate to this. Customer reviews mentioning gastritis improvement (one such review on the DoNotAge wall) are consistent with this local-effect hypothesis but should not be over-interpreted.
Apigenin scavenges reactive oxygen species directly and activates the Nrf2 endogenous antioxidant response.
Apigenin is a polyphenolic antioxidant with direct ROS-scavenging activity (the standard mechanism for flavonoids, mediated by the catechol moiety on the B-ring) and indirect activity via activation of Nrf2 — the master transcription factor for endogenous antioxidant defence, which upregulates expression of glutathione-related enzymes, heme oxygenase-1, and NAD(P)H quinone dehydrogenase 1. The Nrf2 mechanism is shared with several other longevity-relevant flavonoids (sulforaphane, quercetin, fisetin). At realistic plasma concentrations from oral dosing, the direct ROS-scavenging effect of apigenin systemically is likely small relative to the body's own endogenous antioxidant capacity; the Nrf2-mediated upregulation of endogenous defence is the more clinically relevant component.
Apigenin inhibits the aromatase enzyme that converts testosterone to estradiol — the mechanism behind the brand's "can increase testosterone" claim.
Aromatase (CYP19A1) catalyses the conversion of testosterone to estradiol. Multiple flavonoids — apigenin, chrysin, quercetin — inhibit aromatase in cell-based assays. Sanderson et al. (2004) and related work characterise the structure-activity relationship for flavonoid aromatase inhibition. The clinical relevance in humans, however, is debated: oral chrysin (a more potent in-vitro aromatase inhibitor than apigenin) has notoriously poor bioavailability and minimal effect on circulating testosterone in human trials. The same bioavailability concern applies to apigenin. The DoNotAge claim that apigenin "can increase testosterone levels" is mechanistically defensible but should not be read as a demonstrated clinical effect in humans at the recommended dose. Users specifically targeting testosterone optimisation should consult a clinician and rely on blood-test-confirmed measurement rather than expect symptomatic effects from this product.
Apigenin induces cell cycle arrest and apoptosis in a wide range of cancer cell lines in vitro — the basis for the "anticancer" research interest.
Apigenin has been studied extensively in cancer cell-line models, where it produces dose-dependent cell cycle arrest (G2/M phase predominantly), induction of apoptosis via both mitochondrial and death-receptor pathways, and modulation of multiple cancer-relevant signalling pathways (PI3K-Akt, mTOR, NF-κB). The in-vitro evidence base is large (multiple hundreds of papers). The translational status: no human cancer prevention or treatment RCT of apigenin has been completed, and the bioavailability constraints make achieving the in-vitro effective concentrations systemically very challenging. The 2021 Frontiers in Pharmacology review on apigenin for gastrointestinal cancer noted that direct luminal exposure of GI epithelium to dietary apigenin may be a more biologically plausible route to a chemoprevention effect than systemic exposure. Apigenin should not be presented or used as a cancer treatment or prevention substance based on currently available human evidence.
THE INTEGRATED MECHANISTIC PICTURE
Apigenin acts on at least six biologically meaningful pathways. The mechanistic evidence base is substantial — apigenin is one of the more comprehensively-studied dietary flavonoids in the published literature. The translational gap is consistent across all six pathways: in-vitro effective concentrations are in the low-to-mid micromolar range, while plasma concentrations achievable from realistic oral dosing in humans are in the low nanomolar range. Two consequences follow. First, the most clinically plausible mechanisms for Pure Apigenin at 500 mg/day are those that act locally (gastrointestinal anti-inflammatory effects, where luminal concentrations are highest) or those that may be sensitive to lower-dose chronic exposure rather than acute high-concentration spikes (Nrf2-mediated antioxidant defence, CD38 inhibition averaged across long supplementation periods, central benzodiazepine receptor signalling at the tail end of the dose-response curve). Second, claims of dramatic acute effects — "doubles NAD+", "increases testosterone", "anticancer" — should be read as descriptions of mechanism rather than as expected clinical experience at 500 mg/day. The honest user expectation is a modest contribution to longevity-relevant biology, a noticeable calming / sleep-supportive effect for many users, and a meaningful research interest as more human data emerges.
WHAT THE EVIDENCE SUPPORTS
What Pure Apigenin may do for you — honestly
Benefits are listed below in approximate order of evidence strength. The first three rest on a combination of mechanistic plausibility, animal data, and substantial customer-experience consistency. The middle two are mechanistically supported but with translational uncertainty at the 500 mg/day dose. The final two are mechanistically plausible but should be read as research-stage rather than as expected clinical experiences.
THE RESEARCH
What the published evidence shows — for apigenin
The studies below are organised in four groups: (1) the four primary references DoNotAge cites on the product page, with editorial framing of each; (2) additional CD38 / NAD+ literature DoNotAge does not cite; (3) the pharmacokinetic literature that constrains how to interpret all of the above; (4) the broader pharmacological review literature. Where a study used a route, dose, or species substantially different from the 500 mg/day human oral dose at issue, we say so.
Foundational paper identifying apigenin as a potent CD38 inhibitor. In cell culture, apigenin inhibited recombinant CD38 enzymatic activity in the low-micromolar range. In diet-induced obese mice fed apigenin-supplemented chow for 8 weeks, multiple tissues showed approximately doubled NAD+ levels, with concurrent improvements in glucose tolerance, insulin sensitivity, and hepatic steatosis. The paper is the principal scientific basis for the brand's "doubles NAD+" claim. Key caveats for clinical translation: the mouse dose body-surface-area-corrects to approximately 8 mg/kg/day for a human (about 560 mg/day for a 70 kg adult — consistent with the 500 mg/day DoNotAge recommendation); however, achieving in mice the dietary delivery of pure compound chronically is not equivalent to achieving the same plasma exposure in humans via capsule with the known bioavailability constraints. No subsequent human trial has measured NAD+ elevation after oral apigenin supplementation at this dose.
Original identification of apigenin as the principal benzodiazepine-receptor-active component of chamomile flowers. Apigenin displaced [3H]flunitrazepam binding to rat brain synaptosomal membranes with a Ki in the low-micromolar range, and produced anxiolytic-like behavioural effects in mice in the elevated plus-maze paradigm at doses that did not impair motor coordination. The paper is the mechanistic foundation for chamomile's traditional use as a calming herb and for the BZ-receptor explanation of apigenin's calming effect at higher doses than chamomile tea provides. Clinical translation caveat: the behavioural doses (3–10 mg/kg IP in mice) translate by body-surface-area to roughly 17–55 mg for a 70 kg human, but the IP route bypasses the first-pass metabolism that consumes most of the oral apigenin dose — so the equivalent oral human dose is meaningfully higher and matches well with the 500 mg/day DoNotAge recommendation.
Flavonoids isolated from St. John's wort — including biapigenin (a dimeric form of apigenin) — protected cortical neurons against glutamate-induced excitotoxic damage in cell culture. The neuroprotective effect involved reduced calcium overload and modulation of glutamate receptor signalling. Note: the active form in this study was biapigenin, a dimer, rather than the monomeric apigenin in DoNotAge's product. The mechanistic point — flavonoid scaffolds with apigenin-like structure are neuroprotective in vitro against excitotoxic damage — is reasonable to generalise but should not be over-interpreted as a demonstration of effect at the human plasma concentrations achievable from 500 mg/day oral apigenin.
Apigenin and related flavonoids suppressed LPS-induced expression of COX-2 (cyclooxygenase-2) and iNOS (inducible nitric oxide synthase) — two key downstream effectors of NF-κB-mediated inflammatory signalling — in mouse macrophages. The mechanism has since been replicated in many cell types. Clinical translation: the in-vitro concentrations (10–50 μM) substantially exceed plausible human plasma concentrations from 500 mg/day oral dosing. Local effects at gut-mucosal sites with high luminal apigenin exposure are more plausible than systemic anti-inflammatory effects.
Demonstrates that CD38 expression increases markedly with age across multiple tissues, and that CD38 knockout mice maintain higher NAD+ levels into old age with corresponding preservation of mitochondrial function and SIRT3-mediated protein deacetylation. The paper provides the broader scientific context for why CD38 inhibition is a therapeutically attractive target in aging biology — and therefore the rationale for apigenin's specific interest in the longevity supplement space. Critically establishes that the CD38-NAD relationship is causal and age-dependent.
Comprehensive review of apigenin's oral bioavailability. Key findings: relative oral bioavailability approximately 30%; Tmax (time to peak plasma concentration) 0.5–2.5 hours post-dose; elimination half-life 2.52 ± 0.56 hours; large volume of distribution implying significant tissue partitioning; metabolism involves CYP1A and CYP2B with apigenin itself inhibiting CYP3A4 and CYP2C9 (drug interaction implications). The review specifically addresses the gap between in-vitro anticancer activity of apigenin and the realistic systemic concentrations achievable from oral dosing — concluding that direct luminal exposure of GI epithelium to dietary apigenin may be a more biologically plausible route to a chemoprevention effect than systemic exposure. The same analysis applies to any other in-vitro mechanism: systemic effects from oral dosing should not be assumed to match in-vitro concentrations.
One of the few human pharmacokinetic studies of apigenin. After a single large oral apigenin input (delivered via parsley), peak plasma apigenin concentration reached only 33.46 nmol/L at 10 hours post-dose, and fell below the detection limit of 2.3 nmol/L within 28 hours. The critical context for the 500 mg/day Pure Apigenin question: the parsley input in this study delivered far more apigenin than 500 mg of purified compound (even accounting for the glycoside-vs-aglycone bioavailability difference), and yet circulating plasma apigenin concentrations remained in the low nanomolar range — three to four orders of magnitude below the micromolar concentrations at which CD38 inhibition, aromatase inhibition, and anti-inflammatory effects are demonstrated in vitro. This study is the single most important reference for setting realistic expectations about systemic apigenin effects at any oral supplementation dose.
Detailed characterisation of apigenin absorption, metabolism, and excretion in rats. Most absorbed apigenin is rapidly conjugated to glucuronide and sulfate forms; free aglycone apigenin in plasma is a minor fraction of total apigenin-derived material. Urinary excretion of apigenin and its conjugates accounted for 17–33% of the dose, with fecal excretion accounting for an additional 10–29%, implying substantial unabsorbed or biliary-recycled material. The pattern of low free aglycone in plasma plus extensive conjugation is the standard flavonoid pharmacokinetic pattern and constrains the systemic effects achievable from any reasonable oral dose.
Confirmed and extended Viola 1995 — apigenin binds the central benzodiazepine receptor and produces anxiolytic-like behavioural effects in rodents without the sedative, amnestic, or motor-impairing effects of full benzodiazepine agonists. Established the partial-agonist pharmacological profile that distinguishes apigenin's calming effect from prescription benzodiazepines. The paper is the principal mechanistic reference for chamomile's anxiolytic reputation and is directly applicable to interpreting the customer-experience pattern of Pure Apigenin as a sleep / calm-down supplement.
Comprehensive review of apigenin's pharmacological actions across antioxidant, anti-inflammatory, anticancer, neuroprotective, cardiovascular, and metabolic domains. Confirms the broad mechanistic interest in apigenin while consistently noting the gap between in-vitro effective concentrations and achievable plasma levels from oral dosing. Useful as a single reference for the breadth of biological activity; should not be read as a clinical evidence summary.
Review emphasising apigenin's interactions with the gut microbiota. Approximately 5–10% of dietary polyphenol intake is absorbed in the small intestine; the rest reaches the colon, where it is metabolised by gut bacteria. This means a substantial fraction of any oral apigenin dose acts on (and is acted on by) the gut microbiome before any systemic effect, which has implications for both the inter-individual variability of response and for the plausibility of gut-local mechanisms (anti-inflammatory, antimicrobial, gastroprotective) as the most clinically relevant effects at oral dosing.
Self-nanoemulsifying drug delivery systems (SNEDDS) loaded with apigenin produced 3.3–3.8× the oral bioavailability of conventional apigenin powder in rats, via improved solubilisation and transcellular Caco-2 permeability. Conceptually important: formulation matters substantially for apigenin pharmacokinetics. Pure Apigenin from DoNotAge is a conventional capsule formulation; the "bound to beta glycosides" stabilisation claim addresses on-shelf potency rather than bioavailability per se. A future-generation phospholipid-complex or nanoemulsion apigenin product could deliver substantially higher systemic exposure at the same daily milligram input, and that would be the single biggest improvement DoNotAge could make to the product.
Reading these studies together
The published evidence base on apigenin is large, mechanistically rich, and consistently constrained by one pharmacokinetic fact: oral apigenin produces plasma concentrations several orders of magnitude below the in-vitro concentrations at which most of its biological effects have been demonstrated. The mouse CD38 work (Escande 2013) shows that this constraint can be partly overcome by chronic dosing — sustained sub-IC50 exposure can still produce measurable systemic effects over weeks of supplementation. The benzodiazepine receptor mechanism (Viola 1995, Avallone 2000) appears to be the most robust clinical effect at the recommended dose, consistent with the dominant pattern in customer reviews. The anti-inflammatory, antioxidant, aromatase, and antiproliferative mechanisms are mechanistically valid but should be read as supporting the longevity-stack rationale for the product rather than as expected acute clinical effects. The single most actionable conclusion from the evidence base: Pure Apigenin at 500 mg/day is a defensible component of a longevity supplement stack and a defensible nightly calm-down supplement for many users; it is not a substitute for clinician-directed care for any condition. The single most important research gap that DoNotAge could help close is a small human pharmacokinetic study of their specific formulation (250 mg capsule, beta-glycoside-bound) measuring plasma apigenin AUC and free vs conjugated fractions over 24 hours after a single dose — this would substantially clarify the product's expected effect range.
CLINICAL PHARMACOLOGY
From mechanism to plasma — what to actually expect
Apigenin is one of the most thoroughly studied dietary flavonoids in the published literature, with substantive evidence across CD38 inhibition, GABAergic signalling, anti-inflammatory pathways, antioxidant defence, aromatase inhibition, and antiproliferative effects. The translational story is constrained by one pharmacological fact that runs through all six pathways: the in-vitro effective concentrations at which these effects are demonstrated are orders of magnitude above the plasma concentrations achievable from realistic oral dosing in humans. The section below makes that gap explicit, dose by dose and pathway by pathway, so you can read the mechanism section above with appropriately calibrated expectations.
| Pathway | In-vitro effective concentration | Estimated plasma at recommended dose | Gap | Clinical implication |
|---|---|---|---|---|
| CD38 inhibition → NAD+ degradation | IC50 ≈ 10 μM (Escande 2013) | ~10–50 nmol/L (extrapolated from Meyer 2006) | ~200–1000× below | Acute NAD+ doubling at oral dosing is unlikely. Chronic supplementation may still produce a measurable cumulative effect via sustained sub-IC50 exposure — the mechanism by which the Escande mouse result accrued over 8 weeks. |
| GABA-A / benzodiazepine receptor partial agonism | Ki ≈ 4 μM (Viola 1995) | ~10–50 nmol/L | ~80–400× below | Calming subjective effect is reliably observed despite the in-vitro gap. The most clinically usable acute effect of Pure Apigenin at 500 mg/day — supported by mechanism and extensive customer-experience data. |
| NF-κB → COX-2 / iNOS suppression | EC50 ≈ 10–50 μM (Liang 1999) | ~10–50 nmol/L systemic; high micromolar luminal in gut | ~200–5000× below systemically | Systemic anti-inflammatory effect at 500 mg/day is unlikely. Gut-mucosal local effects are plausible because luminal apigenin concentrations before absorption are far higher than circulating plasma levels. |
| Nrf2 → endogenous antioxidant defence | EC50 ≈ 5–20 μM | ~10–50 nmol/L | ~100–2000× below | Modest chronic upregulation of endogenous antioxidant enzymes (HO-1, NQO1, glutathione enzymes) is plausible over weeks of supplementation. Magnitude in humans not directly quantified. |
| Aromatase (CYP19) inhibition | IC50 ≈ 1–5 μM (Sanderson 2004 and related) | ~10–50 nmol/L | ~20–500× below | Clinical testosterone effect at oral dosing unlikely. The mechanism is real and the structure-activity relationship is well-established, but the bioavailability constraint dominates clinical translation. |
| Antiproliferative / pro-apoptotic in transformed cells | EC50 ≈ 10–50 μM (cancer cell lines) | ~10–50 nmol/L | ~200–5000× below | Not a clinical anticancer effect at any oral dose currently studied. Relevant only as a research interest and as a possible component of gut-luminal chemoprevention exploration. |
Dose Translation
How DoNotAge arrived at 500 mg/day — and what that calibration does and doesn't tell us +
The recommended daily dose of 500 mg is internally consistent with the published mouse evidence. Escande et al. (2013) fed diet-induced obese mice an apigenin-supplemented chow that delivered approximately 100 mg of apigenin per kilogram of body weight per day. The standard FDA Body Surface Area (BSA) conversion factor for translating mouse mg/kg doses to human-equivalent mg/kg divides by 12.3. The arithmetic, worked through:
Mouse dose (Escande 2013): 100 mg/kg/day
BSA conversion factor: ÷ 12.3 (FDA, mouse → human)
Human-equivalent dose: 8.13 mg/kg/day
70 kg adult: ≈ 569 mg/day
DoNotAge recommended dose: 500 mg/day
✓ within the BSA- corrected range
What this calibration does NOT tell us: whether the plasma exposure achieved by a 500 mg oral capsule in a human matches the plasma exposure achieved by mouse dietary delivery of the BSA-equivalent dose. That is a separate pharmacokinetic question, dependent on formulation (powder vs phospholipid complex vs nanoemulsion), fed/fasted state, and individual variation in absorption and phase-II conjugation.Drug Interactions
Drug interactions — apigenin inhibits CYP3A4 and CYP2C9 +
Apigenin inhibits two of the body's principal drug-metabolising cytochrome P450 enzymes — CYP3A4 and CYP2C9 — in cell-based assays (DeRango-Adem & Blay 2021). The structural and pharmacological cousin to this interaction is grapefruit, which is itself a well-known CYP3A4 inhibitor producing clinically meaningful drug interactions. Apigenin in the DoNotAge product is synthesized from grapefruit naringin, so the structural analogy is direct. Whether the modest plasma concentrations achievable from 500 mg/day oral apigenin produce clinically meaningful CYP inhibition in humans is not well established; the in-vitro evidence and the grapefruit analogy together justify caution with the medication classes below.
CYP3A4 substrates
Statins: atorvastatin, simvastatin, lovastatin (not pravastatin, rosuvastatin, or fluvastatin — these clear via different routes). Calcium channel blockers: amlodipine, diltiazem, verapamil, felodipine, nifedipine. Immunosuppressants: cyclosporine, tacrolimus, sirolimus, everolimus. Antifungals: ketoconazole, itraconazole, voriconazole, posaconazole. Anti-anxiety and sleep medications: alprazolam, midazolam, triazolam, diazepam. Erectile dysfunction medications: sildenafil, tadalafil, vardenafil. Certain chemotherapy agents: docetaxel, paclitaxel, vincristine, etoposide. Opioids: fentanyl, methadone, oxycodone. Oral contraceptives (ethinyl estradiol). Some HIV protease inhibitors.
CYP2C9 substrates
Warfarin — the classic narrow-therapeutic-window concern. Anyone on warfarin should not start apigenin without prescriber discussion. Phenytoin. NSAIDs: ibuprofen, diclofenac, celecoxib, naproxen. Sulfonylureas for type 2 diabetes: glipizide, glimepiride, tolbutamide. Losartan. The more pharmacologically active S-enantiomer of warfarin is specifically a CYP2C9 substrate.
Bioavailability Optimization
Take with a source of dietary fat +
Apigenin is poorly water-soluble, which is the principal reason its oral bioavailability is only around 30%. Fat in the same meal as the dose improves dissolution in the gut lumen and supports the lymphatic absorption pathway that handles many lipophilic small molecules. Practical: take Pure Apigenin alongside a meal containing some fat (avocado, olive oil, nuts, eggs, fatty fish), or co-administer with a fat-containing supplement such as fish oil, krill oil, or vitamin D3/K2 capsules. The DoNotAge label recommendation already specifies "with a source of fat" — follow it.
Consider splitting the dose for sustained exposure +
Apigenin's elimination half-life is approximately 2.52 hours. A single 500 mg morning dose has substantially decayed plasma concentrations by 6–8 hours later. For chronic mechanisms — CD38 inhibition, Nrf2 activation, anti-inflammatory effects — sustained low-level exposure is mechanistically more relevant than acute spikes. Splitting the dose to 250 mg morning + 250 mg evening produces a flatter exposure profile across the day. For users primarily targeting the acute BZ-receptor calming effect for sleep onset, the conventional single evening dose makes more pharmacological sense — concentrate the peak at the moment of need.
Think chronically — most effects accrue over weeks +
The mouse CD38 evidence (Escande 2013) came from 8 weeks of dietary apigenin supplementation, not from a single high-dose intervention. The Nrf2 transcriptional response upregulates endogenous antioxidant enzyme expression over a similar timescale. The most realistic mental model is daily consistent dosing over months, with cumulative effects emerging rather than visible immediate effects. The exception is the BZ-receptor calming effect, which peaks 30–60 minutes after the dose and is acute. If you do not notice an immediate calming effect, the product may still be doing the slower chronic work — give it 8–12 weeks of consistent use before evaluating whether it is right for you.
Formulation horizon — enhanced-bioavailability versions exist in research +
Self-nanoemulsifying drug delivery systems (SNEDDS) and phospholipid complexes (Phytosome technology) have produced 3–4× improvements in oral apigenin bioavailability in rodent pharmacokinetic studies (Sci Rep 2024). These formulation technologies are well-established for other low-bioavailability flavonoids — curcumin, resveratrol, and quercetin all have commercially available Phytosome or SNEDDS variants. At time of publication, DoNotAge's Pure Apigenin is a conventional powder-in-capsule formulation; no enhanced-bioavailability apigenin product is currently in their catalogue. A future-generation Phytosome or SNEDDS apigenin product would deliver substantially higher systemic exposure at the same milligram input, and is the single most impactful improvement we have requested from the brand.
Special Populations
Pregnancy and breastfeeding +
No specific human safety data exists for apigenin supplementation during pregnancy or lactation. The aromatase-inhibition mechanism (apigenin reduces estradiol synthesis from testosterone in vitro) is a theoretical concern given the central role of estradiol in pregnancy maintenance. Conservative recommendation: avoid Pure Apigenin during pregnancy and while breastfeeding. Dietary apigenin from parsley, celery, and chamomile tea in normal culinary quantities is not a concern; supplemental doses are.
Children and adolescents under 18 +
No paediatric safety, efficacy, or dosing data exists for apigenin supplementation. Pure Apigenin is not recommended for users under 18 years of age. Adolescents with sleep, anxiety, or other concerns should be evaluated by a clinician rather than self-treated with adult-dosed supplements.
Concurrent benzodiazepines, Z-drugs, or alcohol +
Apigenin acts at the central benzodiazepine binding site on the GABA-A receptor as a partial agonist (Viola 1995). Stacking with prescription benzodiazepines (alprazolam, diazepam, lorazepam, clonazepam), Z-drugs (zolpidem, eszopiclone, zaleplon), heavy alcohol use, or other CNS depressants produces additive central nervous system suppression with potential for excessive sedation. Users on any of these medications should discuss apigenin supplementation with their prescriber before starting, and should not combine with alcohol.
Narrow-therapeutic-window medications +
Apigenin's CYP3A4 and CYP2C9 inhibition (see Drug interactions block above) creates particular concern for medications whose effective dose is close to their toxic dose. The classic example is warfarin, where small changes in plasma concentration can produce clinically meaningful changes in INR and bleeding risk. Other concerns: immunosuppressants (cyclosporine, tacrolimus) where over-exposure raises infection and nephrotoxicity risk, certain antiarrhythmics, and some chemotherapy regimens. Anyone on any of these should not start Pure Apigenin without prescriber discussion.
Hormonally-mediated cancers (breast, prostate, endometrial) +
Apigenin's aromatase-inhibition mechanism is well-characterised in vitro and is the basis for the brand's "testosterone increase" claim. The same mechanism — lowering circulating estradiol — is therapeutically relevant in hormone-receptor-positive breast cancer treatment (e.g. letrozole, anastrozole). Whether the modest plasma concentrations achievable from 500 mg/day oral apigenin meaningfully affect aromatase activity in vivo is not established, but the theoretical concern justifies caution. Anyone with a history of hormonally-mediated cancer should consult their oncologist before starting Pure Apigenin or any phytoestrogen or aromatase-modulating supplement.
Severe hepatic or renal impairment +
Apigenin is primarily metabolised in the liver via phase II conjugation (glucuronidation and sulfation) and excreted through both biliary and renal routes. In advanced liver disease (Child-Pugh C cirrhosis), reduced conjugation capacity could prolong apigenin exposure and increase the risk of any concentration-dependent effects, including CYP inhibition. Renal clearance plays a smaller role but is still relevant in stage 4–5 chronic kidney disease. Users with significant hepatic or renal impairment should discuss with their clinician before starting Pure Apigenin; for most healthy adults with normal organ function, no specific dose adjustment is needed.
THE CLINICAL TAKEAWAY
Apigenin's clinical pharmacology can be summarised in one sentence: the mechanistic biology is rich and well-characterised, while the realistic systemic effects at 500 mg/day oral dosing are constrained by an oral bioavailability of approximately 30% and a strong tendency to phase-II conjugation after absorption. The clinically usable effects at this dose appear to be the benzodiazepine-receptor-mediated calming effect (well-supported by both mechanism and customer-experience data), a chronic contribution to NAD+ pool maintenance via sustained CD38 inhibition (mouse-evidenced, human-unquantified), and gut-mucosal anti-inflammatory effects (plausible local mechanism). The acute, dramatic effects sometimes attributed to apigenin in marketing copy — rapid NAD+ doubling, measurable testosterone increases, anticancer effects — should be understood as descriptions of mechanism rather than expected clinical experiences. Within those honest limits, Pure Apigenin remains one of the more reasoned single-ingredient supplements in the longevity space, and is a defensible component of a longevity stack for most users without contraindications.
Frequently asked about Pure Apigenin
Apigenin (chemically 4',5,7-trihydroxyflavone) is a plant flavone — a small molecule from the broader flavonoid family — naturally present in parsley, celery, chamomile, and (the source DoNotAge uses) grapefruit. It is in this product for two distinct reasons that the brand and its customers tend to emphasise differently. The brand emphasises apigenin as one of the most potent natural inhibitors of the NAD-consuming enzyme CD38; in mice, apigenin supplementation approximately doubles tissue NAD+ levels (Escande 2013), and CD38 inhibition is a research-validated lever for slowing the age-related decline in NAD+ (Camacho-Pereira 2016). Customer reviews emphasise apigenin's calming and sleep-supporting effect via its action at the central benzodiazepine receptor (Viola 1995; Avallone 2000) — the same mechanism that gives chamomile tea its calming reputation. Both are real; the editorial copy on this page addresses both.
Honest answer: the evidence that apigenin doubles NAD+ is mouse data, not human data. The Escande 2013 paper showed that diet-induced obese mice fed apigenin-supplemented chow (approximately 100 mg/kg/day, which body-surface-area-corrects to about 8 mg/kg/day in humans — broadly consistent with the 500 mg/day dose here) experienced approximately doubled tissue NAD+ levels over 8 weeks. No human RCT has measured NAD+ elevation after oral apigenin supplementation at 500 mg/day. There are two reasons to be cautious about expecting a 2× human NAD+ effect: (1) oral apigenin has poor bioavailability (~30%) and is extensively conjugated after absorption, so circulating free apigenin in humans is in the low nanomolar range — orders of magnitude below the micromolar concentrations at which CD38 is inhibited in vitro; (2) sustained low-dose exposure can still produce measurable effects over weeks of supplementation (this is part of the mouse finding), so the absence of an acute spike does not necessarily mean the absence of a chronic benefit. Realistic expectation: a modest contribution to NAD+ pool maintenance, most useful when stacked with an NAD+ precursor such as NMN that raises synthesis while apigenin slows degradation.
Apigenin is poorly soluble in water and is heavily conjugated to glucuronide and sulfate forms after intestinal absorption. The conjugated forms are biologically much less active than free apigenin aglycone. Approximately 5–10% of dietary polyphenol intake (apigenin included) is absorbed intact in the small intestine; the rest reaches the colon and is metabolised by gut bacteria (Wang 2019). The relative oral bioavailability is around 30% based on rodent pharmacokinetic studies; human plasma concentrations after realistic oral doses sit in the low nanomolar range (Meyer 2006: 33.46 nmol/L peak after a 2 g/kg parsley dose). This is the single biggest pharmacological constraint on what oral apigenin can do systemically — and the reason future formulation work (phospholipid complexes, self-nanoemulsifying drug delivery systems) showing 3–4× bioavailability improvements is so interesting (Nature 2024).
DoNotAge describes Pure Apigenin as "bound to beta glycosides" to maintain on-shelf potency. In plain language: apigenin in nature exists predominantly not as the free aglycone (the form shown in textbooks) but as glycosides — apigenin attached to a sugar moiety via a β-glycosidic bond. The most common natural form is apiin (apigenin-7-apiosylglucoside), found in parsley. Glycosides are more water-soluble and more chemically stable than free apigenin aglycone. After oral ingestion, β-glucosidase enzymes in the gut hydrolyse the glycoside, releasing free apigenin for absorption. The specific glycoside form in DoNotAge's product is not publicly disclosed; this would meaningfully affect pharmacokinetics if specified (apiin, for example, has different absorption kinetics than apigenin-7-glucoside). We have requested specification from DoNotAge; we will update this answer when documentation becomes available.
DoNotAge sources apigenin from grapefruit. The grapefruit is processed to extract naringin (a flavanone glycoside abundant in grapefruit), which is then converted to apigenin via a multi-step chemical process. The starting material is plant-derived; the final molecule is the product of a synthetic conversion. "Naturally derived" is technically accurate but distinct from "naturally extracted intact." For practical purposes, the apigenin molecule that ends up in the capsule is the same molecule whether it is extracted intact from parsley or synthesized from grapefruit naringin — the molecule is the molecule. The synthetic route is a manufacturing decision around scalability, cost, and purity, not a quality compromise.
Many users find it does, based on apigenin's action at the central benzodiazepine receptor (Viola 1995; Avallone 2000). The mechanism is the same one that gives chamomile tea its calming effect, delivered at a substantially higher dose (500 mg of pure apigenin vs the small amount of apigenin in a cup of chamomile tea). The published evidence base is mechanistic and animal-behavioural rather than human RCT; the customer-experience evidence in the 100+ reviews on the DoNotAge product page is substantial and consistent. Honest expectation: a noticeable calming effect within 30–60 minutes of dosing for many users, more reliably than from a cup of chamomile tea, but not a substitute for treatment of clinical insomnia. Users with severe sleep-onset insomnia or chronic sleep maintenance problems should consult a sleep physician; users with mild-to-moderate evening tension or occasional difficulty winding down are the natural target audience.
Chamomile tea provides a small dose of apigenin — most estimates put a cup at 1–5 mg of apigenin, depending on the chamomile concentration and the steeping time. Pure Apigenin at 500 mg/day delivers approximately 100–500× the apigenin input of a typical cup of chamomile tea. The mechanism is the same (central benzodiazepine receptor partial agonism), so users who notice an effect from chamomile tea can reasonably expect a larger and more reliable effect from this product. Users who do not notice any effect from chamomile tea may still benefit from Pure Apigenin at the higher dose, since the dose-response curve at the BZ receptor is non-linear and many users may need the higher input to cross the perception threshold.
Yes — this is the standard stacking recommendation and the mechanistic rationale is sound. NMN (nicotinamide mononucleotide) is a precursor that raises NAD+ synthesis; apigenin inhibits CD38 and thereby slows NAD+ degradation. Stacking the two creates a more durable NAD+ pool than either intervention alone — "raise the inflow and slow the outflow." DoNotAge specifically recommends pairing Pure Apigenin with Pure NMN, and customer reviews repeatedly describe the combination favourably. No pharmacological interaction concerns exist between the two — they act on different enzymes in different parts of the NAD+ metabolic pathway.
DoNotAge's own recommendation is to stack Pure Apigenin with Pure NMN, Pure Vitamin D3/K2/Magnesium, and SIRT6Activator. The pharmacological logic: NMN supplies NAD+ substrate, apigenin slows NAD+ degradation via CD38, SIRT6Activator targets the downstream NAD+-dependent deacetylase SIRT6, and the D3/K2/Magnesium stack covers the foundational cofactor layer. No pharmacological interaction concerns exist among these. TMG (trimethylglycine) is methylation-pathway support, also non-interactive with apigenin. The realistic question is not whether the stack is safe — it is — but whether the marginal benefit of each additional component justifies its cost. For users newly building a longevity supplement stack, Pure NMN plus Pure Apigenin is the highest-rationale starting pair.
DoNotAge recommends taking with a source of dietary fat, any time of day. Two practical considerations modify this: (1) the calming, BZ-receptor-mediated effect peaks 30–60 minutes after dosing — users primarily targeting sleep onset should take it 30–60 minutes before bed; (2) the elimination half-life of approximately 2.52 hours means the calming effect has substantially decayed by 5–6 hours after dosing, so for users targeting morning calmness an earlier evening dose may give a flatter day-night exposure profile. The fat-with-dose recommendation reflects the poor water solubility of apigenin — pairing with a fatty meal (or with a fat-containing supplement such as fish oil or vitamin D capsules) can modestly improve absorption.
Caution is appropriate, particularly with medications metabolised by CYP3A4 or CYP2C9. Apigenin inhibits both CYP3A4 and CYP2C9 in vitro (Frontiers Pharm 2021 review), which means that at high enough plasma concentrations apigenin could slow the clearance of drugs metabolised by these enzymes — increasing their plasma levels and the risk of side effects. The classes of medication potentially affected include: statins (particularly simvastatin, atorvastatin), some calcium channel blockers, certain antifungals, oral contraceptives, warfarin, and many anti-anxiety / anti-depressant medications. The same concern applies broadly to grapefruit consumption — grapefruit is a well-known CYP3A4 inhibitor — and is part of why grapefruit-derived apigenin shares this caution. Whether the modest plasma concentrations achievable from 500 mg/day oral apigenin actually produce clinically meaningful CYP inhibition in humans is not well-established. Conservative recommendation: anyone taking prescription medications with a narrow therapeutic window (warfarin, certain immunosuppressants, certain anti-arrhythmics) should consult their prescriber before starting Pure Apigenin. Anyone on benzodiazepines, sleeping pills, or other CNS sedatives should also discuss with their prescriber, given apigenin's BZ-receptor activity.
Honest answer: probably not detectably, at 500 mg/day oral dosing. The mechanistic basis is real — apigenin inhibits aromatase (the enzyme that converts testosterone to estradiol) in cell-based assays, and aromatase inhibition is a legitimate pharmacological strategy for raising testosterone. But the in-vitro IC50 for aromatase inhibition by apigenin is in the micromolar range, while plasma concentrations from 500 mg/day oral dosing are in the low nanomolar range. The structurally related flavonoid chrysin (a more potent in-vitro aromatase inhibitor than apigenin) has been studied for this purpose in humans and consistently shows little or no measurable testosterone effect — the bioavailability constraint is the dominant problem. Users specifically targeting testosterone optimisation should rely on baseline labs and clinician-directed intervention rather than expect symptomatic effects from this product.
The anticancer claim references in-vitro and animal data showing apigenin produces dose-dependent cell cycle arrest and apoptosis in cancer cell lines. No human cancer prevention or treatment RCT of apigenin has been completed; the in-vitro effective concentrations are above what oral 500 mg/day plausibly delivers systemically. Apigenin should not be used as a cancer treatment or prevention substance based on current human evidence. The DoNotAge mention of "anticancer agent" properties reflects the in-vitro literature accurately but should be understood as describing a mechanistic research interest, not a demonstrated clinical benefit. Users with active cancer should consult their oncologist before starting any new supplement — apigenin's CYP3A4 inhibition could in principle affect chemotherapy drug levels.
Pregnant or breastfeeding women — no specific safety data in pregnancy; in vitro effects on aromatase and on cytochrome P450 enzymes warrant caution. Children and adolescents under 18 — no paediatric safety data. Anyone on benzodiazepines, Z-drugs (zolpidem, eszopiclone), or other CNS sedatives — additive sedation possible via shared BZ-receptor mechanism; do not stack without medical supervision. Anyone on warfarin or other medications with a narrow therapeutic window metabolised by CYP3A4 or CYP2C9 — potential drug interaction; consult prescriber. Anyone with hormonally-mediated cancers (some breast and prostate cancers) — apigenin's aromatase activity is in vitro but caution warranted; consult oncologist. Anyone with a known flavonoid sensitivity or grapefruit allergy.
Pure Apigenin is generally well-tolerated at the recommended 500 mg/day dose. The most common subjective experience is the intended calming effect within 30–60 minutes of dosing — most users find this pleasant; some users may find it sedating during the day. A small number of customer reviews mention cold-sore (herpes labialis) reactivation; the mechanism is unclear and the association is anecdotal rather than established. Rare effects: mild GI upset, vivid dreams (consistent with a BZ-receptor-modulated REM sleep architecture), morning grogginess if dosed too close to bedtime (less common given the relatively short half-life). The 100+ customer reviews on the DoNotAge page report no serious adverse events. Users new to apigenin may want to start at half the recommended dose (250 mg/day = 1 capsule) for the first 3–5 days and titrate up to 500 mg/day if well-tolerated.
Yes if you plan to use the product long term. The economics are unambiguous: at the 500 mg/day recommended dose, the annual subscription tier costs $320/year ($0.88/day), versus one-time purchase of 60-cap tubs at $55 each which would cost approximately $670/year ($1.83/day) for the same daily input. The 366-capsule one-time tub at $250 is the middle option — better value than the 60-cap tub, less economical than the subscription. The 52% subscription discount is genuine on this SKU and applies cleanly across the dose tiers (250 mg, 500 mg, 750 mg, 1 g daily). Two cautions before subscribing: (1) the annual shipment arrives as a single bulk delivery, so you should be confident the product agrees with you before committing to a year's supply; running a one-month 60-cap tub first is the safer entry point; (2) the higher subscription dose tiers (750 mg/day, 1 g/day) are above the standard recommended dose and there is no specific evidence base supporting them — most users have no reason to choose above the 500 mg/day tier.
At $0.88/day on the 500 mg/day annual subscription (or $0.79/day after BB10 discount applied to first month if subscription supports it), Pure Apigenin is reasonably priced for a single-ingredient, third-party-tested, 99%+ purity longevity supplement at a defined dose. The principal value proposition is the combination of (a) one of the more mechanistically interesting NAD+-supporting molecules, (b) a noticeable calming effect for many users via the well-established BZ-receptor mechanism, and (c) the convenience of a single capsule format at a defined dose. Honest editorial position: this is one of the better-reasoned single-ingredient products in DoNotAge's catalogue and is a defensible component of a longevity stack alongside Pure NMN. The principal weakness is the bioavailability constraint, which is shared with virtually every other apigenin product on the market — a future-generation phospholipid-complex or nanoemulsion formulation would be a meaningful upgrade if and when DoNotAge develops one.
Your protocol starts here
Ready to inhibit CD38, restore NAD+, and unlock deeper sleep?
Purchase directly from the manufacturer using our clinical code to guarantee authenticity and the lowest available price.
We earn a commission when you purchase through this link or use the discount code. This relationship funds our independent medical reviews.